1. Analysis of a Phase 2b Study of GEN-003, a Genital Herpes Immunotherapy, Showed Significant Reductions in Viral Shedding and Lesion Rate Vs Placebo. (4th October 2017) Authors: Heineman, Thomas C; Bernstein, David; Wald, Anna; Van Wagoner, Nicholas; Leone, Peter; Mayer, Kenneth; Lucksinger, Gregg; Win, Sandra; Koltun, William; Desai, Nisha; Oliphant, Thomas; Natenshon, Andrew; McNeil, Lisa K; Flechtner, Jessica B; Hetherington, Seth Journal: Open forum infectious diseases Issue: Volume 4(2017)Supplement 1 Page Start: S59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Significant Neutralizing Antibody and Cytolytic T Cell Responses to GEN-003, a Herpes Simplex Virus Immunotherapy, in a Phase 2b Study. (4th October 2017) Authors: McNeil, Lisa K; Baccari, Amy; Clemens, Veronica; Dominguez, David; Fenske, Tyler; Oliphant, Thomas; Perry, James; Siddall, Nicolle; Yuan, Jin; Heineman, Thomas; Hetherington, Seth; Flechtner, Jessica B Journal: Open forum infectious diseases Issue: Volume 4(2017)Supplement 1 Page Start: S519 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Sustained Lesion and Shedding Rate Reductions in Genital Herpes Patients 24 Months after Immunization with GEN-003, a Genital Herpes Immunotherapy. (4th October 2017) Authors: Heineman, Thomas; Mcneil, Lisa K; Oliphant, Thomas; Natenshon, Andrew; Van Wagoner, Nicholas; Flechtner, Jessica B; Hetherington, Seth Journal: Open forum infectious diseases Issue: Volume 4(2017)Supplement 1 Page Start: S309 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗